PL2118098T3 - Postacie polimorficzne makrocyklicznego inhibitora HCV - Google Patents

Postacie polimorficzne makrocyklicznego inhibitora HCV

Info

Publication number
PL2118098T3
PL2118098T3 PL08708575T PL08708575T PL2118098T3 PL 2118098 T3 PL2118098 T3 PL 2118098T3 PL 08708575 T PL08708575 T PL 08708575T PL 08708575 T PL08708575 T PL 08708575T PL 2118098 T3 PL2118098 T3 PL 2118098T3
Authority
PL
Poland
Prior art keywords
hcv
polymorphic forms
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
PL08708575T
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Kelly Ann Swinney
Stijn Wuyts
Andras Horvath
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2118098(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PL2118098T3 publication Critical patent/PL2118098T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08708575T 2007-02-01 2008-02-01 Postacie polimorficzne makrocyklicznego inhibitora HCV PL2118098T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01
EP08708575.9A EP2118098B1 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv
PCT/EP2008/051268 WO2008092954A2 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number Publication Date
PL2118098T3 true PL2118098T3 (pl) 2015-03-31

Family

ID=38229348

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08708575T PL2118098T3 (pl) 2007-02-01 2008-02-01 Postacie polimorficzne makrocyklicznego inhibitora HCV

Country Status (25)

Country Link
US (1) US8143402B2 (pl)
EP (1) EP2118098B1 (pl)
JP (1) JP5523110B2 (pl)
KR (1) KR101580226B1 (pl)
CN (3) CN101589040A (pl)
AR (2) AR065136A1 (pl)
AU (1) AU2008209696B2 (pl)
BR (1) BRPI0806945A2 (pl)
CA (1) CA2677170C (pl)
CL (1) CL2008000321A1 (pl)
CY (1) CY1116339T1 (pl)
DK (1) DK2118098T3 (pl)
ES (1) ES2524784T3 (pl)
HK (1) HK1205125A1 (pl)
HR (1) HRP20141137T1 (pl)
IL (1) IL199215A (pl)
MX (1) MX2009008275A (pl)
NZ (1) NZ577568A (pl)
PL (1) PL2118098T3 (pl)
PT (1) PT2118098E (pl)
RU (1) RU2533830C2 (pl)
SI (1) SI2118098T1 (pl)
TW (1) TWI423968B (pl)
WO (1) WO2008092954A2 (pl)
ZA (1) ZA200905377B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PT2401272T (pt) * 2009-02-27 2017-02-28 Janssen Pharmaceuticals Inc Sal amorfo de um inibidor macrocíclico de hcv
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
AU2011209051B2 (en) 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
EP2704576A4 (en) * 2011-05-04 2014-12-10 Merck Sharp & Dohme METHOD FOR THE PRODUCTION OF INHIBITORS OF HEPATITIS C VIRUS
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
CA2848229C (en) * 2011-09-16 2019-08-27 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515216A1 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
RU2006113880A (ru) * 2003-09-26 2007-11-20 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP4902361B2 (ja) * 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
KR20090115929A (ko) 2009-11-10
CN105037347B (zh) 2018-06-01
SI2118098T1 (sl) 2015-01-30
AU2008209696B2 (en) 2013-05-09
AU2008209696A1 (en) 2008-08-07
EP2118098B1 (en) 2014-09-24
IL199215A (en) 2015-10-29
RU2533830C2 (ru) 2014-11-20
AR065136A1 (es) 2009-05-20
HRP20141137T1 (hr) 2015-01-30
KR101580226B1 (ko) 2015-12-24
HK1205125A1 (en) 2015-12-11
CY1116339T1 (el) 2017-02-08
WO2008092954A8 (en) 2009-12-23
CN104230918B (zh) 2018-01-26
ZA200905377B (en) 2010-10-27
CN101589040A (zh) 2009-11-25
CN105037347A (zh) 2015-11-11
JP5523110B2 (ja) 2014-06-18
EP2118098A2 (en) 2009-11-18
HK1137438A1 (en) 2010-07-30
US20100029715A1 (en) 2010-02-04
MX2009008275A (es) 2009-08-12
CN104230918A (zh) 2014-12-24
CL2008000321A1 (es) 2008-08-22
PT2118098E (pt) 2014-12-09
WO2008092954A2 (en) 2008-08-07
JP2010517971A (ja) 2010-05-27
TW200846347A (en) 2008-12-01
US8143402B2 (en) 2012-03-27
BRPI0806945A2 (pt) 2014-05-06
RU2009132660A (ru) 2011-03-10
CA2677170A1 (en) 2008-08-07
NZ577568A (en) 2012-02-24
TWI423968B (zh) 2014-01-21
CA2677170C (en) 2017-04-18
DK2118098T3 (en) 2014-12-08
WO2008092954A3 (en) 2008-10-02
AR108819A2 (es) 2018-09-26
ES2524784T3 (es) 2014-12-12

Similar Documents

Publication Publication Date Title
ZA200905377B (en) Polymorphic forms of a macrocyclic inhibitor of HCV
PL2121674T3 (pl) Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV
IL195029A0 (en) Polymorphs
IL210345A0 (en) Crystalline forms of a 2 - thiazolyl - 4 - quinolinyl - oxy derivative, a potent hcv inhibitor
PT2094708E (pt) Pirrolopirazina como inibidor da cinase syk
EP1978966A4 (en) TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
AP2009004812A0 (en) HCV nucleoside inhibitor
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
IL199640A0 (en) Hcv inhibiting macrocyclic phenylcarbamates
EP2036894A4 (en) AURORA INHIBITOR
IL196706A0 (en) Crystalline forms of rapamycin analogs
IL243058A0 (en) Amorphous salt of macrocyclic hcv inhibitor
IL213246A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
EP2123272A4 (en) ADAM INHIBITORS
GB201002676D0 (en) Inhibition of alpha synuclein toxicity
ZA200903609B (en) Motilide polymorphs
GB0623381D0 (en) Use of a compound as VEGF inhibitor
EP1983997A4 (en) CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
GB0619888D0 (en) New polymorphic forms of pregabalin
ZA200900740B (en) Crystalline forms of rapamycin analogs
GB0700807D0 (en) A method of printing
GB0617364D0 (en) Inflatable show junp
GB0720364D0 (en) Inhibitor
GB0700742D0 (en) A method of syndicating a property